Oryzon Genomics S.A.

Oryzon Genomics S.A.

ORYZF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$253.86M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Oryzon Genomics S.A.Oryzon Genomics S.A.-75.2--2%--
$0.24

Current Fair Value

92.1% downside

Overvalued by 92.1% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$253.86 Million
Enterprise Value$245.01 Million
Earnings per Share$-0.04
Beta0.45
Outstanding Shares81,925,454

Return

Return on Equity-1.97%ROE
Return on Assets-1.68%
Return on Invested Capital-5.52%

Valuation & Multiples

P/E Ratio-75.19P/E Ratio
PEG-21.26PEG
Price to Sales-Price to Sales
Price to Book Ratio3.1Price to Book Ratio
Enterprise Value to Revenue28.19
Enterprise Value to EBIT-34.15
Enterprise Value to Net Income-104
Total Debt to Enterprise0.02
Debt to Equity0.05Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 16, 2026
EPS
-$0.02
Est. -$0.07
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 4, 2027
EPS Estimate
-$0.06
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Oryzon Genomics S.A.

46 employees
CEO: Carlos Manuel Buesa Arjol

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical firm dedicated to the discovery and advancement of epigenetics-based therapies. Its primary focus is on treating cancer and central nervous system (CNS) disorders. The company's ...